Jun Zhou

Jun Zhou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
XZXinyue Zhang
Xinyue Zhang
JZJun Zhou
Jun Zhou
MGMengyuan Guo
Mengyuan Guo
SCShirui Cheng
Shirui Cheng
YCYilin Chen
Yilin Chen
FZFang Zeng
Fang Zeng

18 August 2025 in Brain Research
Verified
Journal Article
Closed access
YWYangyang Wang
Yangyang Wang
YZYuanfang Zhou
Yuanfang Zhou
HTHao Tian
Hao Tian
QLQifu Li
Qifu Li
YCYan Chen
Yan Chen
FLFan-rong Liang
Fan-rong Liang

18 August 2026 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
QLQifu Li
Qifu Li
YCYan Chen
Yan Chen
YWYangyang Wang
Yangyang Wang
ZCziwen chen
ziwen chen
YLYunnan Liu
Yunnan Liu
FLFan-rong Liang
Fan-rong Liang
Fatigue is a prevalent and disabling non-motor symptom in Parkinson’s disease (PD), significantly impairing patients’ quality of life. Non-inva

19 November 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
QLQifu Li
Qifu Li
YSYuquan Shen
Yuquan Shen
YWYangyang Wang
Yangyang Wang
JLJunxia Liu
Junxia Liu
ZCZiwen Chen
Ziwen Chen
FLFan-rong Liang
Fan-rong Liang
Introduction: Motor dysfunction, including bradykinesia, rigidity, tremor, and gait disturbance, is the core clinical feature of Parkinson’s disease (PD) and a major cause of disability. In early-stage PD (Hoehn and Yahr ≤2.5), neurodegeneration is relatively mild, and timely intervention may help preserve motor function and delay progression. Although dopaminergic medications effectively alleviate motor symptoms, their long-term use is associated with motor fluctuations and levodopa-induced dyskinesia. Acupuncture, a low-risk, well-tolerated intervention, has shown potential in improving motor performance in PD, but high-quality evidence in early-stage patients is lacking. Methods and analysis: This single-blind, sham-controlled randomized clinical trial will enroll 120 patients with early-stage PD (disease duration ≤3 years). Participants will be randomly assigned in a 1:1 ratio ( n = 60 per group) to the true acupuncture (TA) or sham acupuncture (SA) group using stratified block randomization (block size 4) by study center. Treatment will be administered three times weekly for 12 weeks, with follow-up to 15 months. The primary outcome is the change in composite clinical motor score (CCMS) from baseline to week 12. The secondary outcomes include Movement Disorder Society unified Parkinson’s disease rating scale (MDS-UPDRS), Purdue Pegboard Test score (PPTS), Timed Up and Go Test (TUG), 6-min walk test (6MWT), Non-Motor Symptoms Scale (NMSS), 39-item Parkinson’s Disease Questionnaire (PDQ-39), Clinical Global Impression Scale (CGI), and levodopa equivalent daily dose (LEDD). Acupuncturists will not be blinded while participants, outcome assessors, and data analysts remain blinded. The primary analysis will use intention-to-treat (ITT) with mixed-effects models for longitudinal changes, handling missing data via multiple imputation by chained equations. Discussion: This study aimed to evaluate the efficacy and safety of acupuncture in improving motor function in early-stage PD. The results will help determine its potential role as an adjunctive therapy to preserve motor function. Clinical trial registration: https://itmctr.ccebtcm.org.cn/ , identifier ITMCTR2025001290.